Table 1.

Characteristics, mutational profiles and HIV-1 subtype identified in the study population

IDHIV-1 pVL (log10 copies/mL)Time on RAL (months)INI DRMsPredicted drug resistance to:
HIV-1 subtype in IN
HIV-1 subtype in PR-RT
RALEVGDTGBICphylogenetic and recombination analysisStanford HIVdb genotypingphylogenetic and recombination analysisStanford HIVdb genotyping
AR_4610084.9230T97A, Y143RHLSSBBBB
AR_470449BIS5.5457G140S, Q148HHHIIBBURF_BFB
AR_4851965.0814L74M, T97A, Y143R, E138KHILLBBBB
AR_4856305.1527Y143RHSSSBBBB
AR_4880904.768G140S, Q148H, E138KHHHHBBURF_BFB
AR_4973394.7911G140S, Q148H, E138KHHHHBBBB
AR_5856_AA323RED4.7342G140S, Q148HHHIIBBURF_BFB
AR_4815944.4121T97A, Q148R, E138K, S147G, V151I/VHHHHBBFF
AR_4757362.8523L74M, N155H, V151I, G163RHHSSFBCRF29_BFCRF29_BF
AR_4775513.6930SSSSFFURF_BFCRF12_BF
AR_4819604.79SSSSFFCRF12_BFCRF12_BF
AR_4870955.317L74I/M, T97A, P142T, G163KLLSSFFURF_BFB + F
AR_4900824.4911T97A, Y143RHLSSFFCRF12_BFCRF12_BF
AR_4958524.6042L74M, T97A, Y143RHISSFFURF_BFB + F
AR_598_X785RYL4.2636G163KLLSSFFURF_BFB + F
AR_4973976.0176SSSSFFURF_BFB + F
AR_5155_T723GM6.0212L74M, T97A, Y143RHISSFFURF_BFB+F
AR_4363_W359PMME3.6810N155N/HHHSSFFCRF12_BFCRF12_BF
AR_3080_AA714DTJL3.2828T97A, G163RLLSSFFCRF17_BFB
AR_5793_AA770PG2.9522N155H, G163RHHSSFFURF_BFB + F
AR_2337_AA807FLA4.728SSSSFFURF_BFB + F
AR_3174_AA185BIL4.088SSSSFFURF_BFB
AR_49004773G140S, Q148HHHIIURF_BFFURF_BFB
AR_3013_W812BDMS3.6342V151I, N155HHHSSURF_BFBURF_BFB
AR_3302_Y937LLN4.5219G140S, Q148HHHIIURF_BFBURF_BFB
AR_568_Z708GGA4.9727G140S, Q148HHHIIURF_BFBURF_BFB
AR_6462_AA893CP4.6217L74I, G140S, Q148H, E138AHHHHURF_BFFCRF12_BFCRF12_BF
AR_6286_AA416RBBJ4.7612N155HHHSSURF_BFFURF_BFB + F
AR_3128_Z059UTA3.4231SSSSURF_BFFURF_BFB
AR_4725846.6235T97A, V151I, N155HHHSS?CRF05_DFCRF05_DFCRF05_DF
IDHIV-1 pVL (log10 copies/mL)Time on RAL (months)INI DRMsPredicted drug resistance to:
HIV-1 subtype in IN
HIV-1 subtype in PR-RT
RALEVGDTGBICphylogenetic and recombination analysisStanford HIVdb genotypingphylogenetic and recombination analysisStanford HIVdb genotyping
AR_4610084.9230T97A, Y143RHLSSBBBB
AR_470449BIS5.5457G140S, Q148HHHIIBBURF_BFB
AR_4851965.0814L74M, T97A, Y143R, E138KHILLBBBB
AR_4856305.1527Y143RHSSSBBBB
AR_4880904.768G140S, Q148H, E138KHHHHBBURF_BFB
AR_4973394.7911G140S, Q148H, E138KHHHHBBBB
AR_5856_AA323RED4.7342G140S, Q148HHHIIBBURF_BFB
AR_4815944.4121T97A, Q148R, E138K, S147G, V151I/VHHHHBBFF
AR_4757362.8523L74M, N155H, V151I, G163RHHSSFBCRF29_BFCRF29_BF
AR_4775513.6930SSSSFFURF_BFCRF12_BF
AR_4819604.79SSSSFFCRF12_BFCRF12_BF
AR_4870955.317L74I/M, T97A, P142T, G163KLLSSFFURF_BFB + F
AR_4900824.4911T97A, Y143RHLSSFFCRF12_BFCRF12_BF
AR_4958524.6042L74M, T97A, Y143RHISSFFURF_BFB + F
AR_598_X785RYL4.2636G163KLLSSFFURF_BFB + F
AR_4973976.0176SSSSFFURF_BFB + F
AR_5155_T723GM6.0212L74M, T97A, Y143RHISSFFURF_BFB+F
AR_4363_W359PMME3.6810N155N/HHHSSFFCRF12_BFCRF12_BF
AR_3080_AA714DTJL3.2828T97A, G163RLLSSFFCRF17_BFB
AR_5793_AA770PG2.9522N155H, G163RHHSSFFURF_BFB + F
AR_2337_AA807FLA4.728SSSSFFURF_BFB + F
AR_3174_AA185BIL4.088SSSSFFURF_BFB
AR_49004773G140S, Q148HHHIIURF_BFFURF_BFB
AR_3013_W812BDMS3.6342V151I, N155HHHSSURF_BFBURF_BFB
AR_3302_Y937LLN4.5219G140S, Q148HHHIIURF_BFBURF_BFB
AR_568_Z708GGA4.9727G140S, Q148HHHIIURF_BFBURF_BFB
AR_6462_AA893CP4.6217L74I, G140S, Q148H, E138AHHHHURF_BFFCRF12_BFCRF12_BF
AR_6286_AA416RBBJ4.7612N155HHHSSURF_BFFURF_BFB + F
AR_3128_Z059UTA3.4231SSSSURF_BFFURF_BFB
AR_4725846.6235T97A, V151I, N155HHHSS?CRF05_DFCRF05_DFCRF05_DF

Mutations contributing to INI susceptibility according to the Stanford HIVdb program are shown in bold. Mutations known as major are underlined.

pVL, plasma viral load; RAL, raltegravir; EVG, elvitegravir; DTG, dolutegravir; BIC, bictegravir; S, susceptible; H, high-level resistant; I, intermediate-level resistant; L, low-level resistant;—, no mutation detected by Sanger sequencing; ?, could not be confirmed by phylogenetic analysis.

Table 1.

Characteristics, mutational profiles and HIV-1 subtype identified in the study population

IDHIV-1 pVL (log10 copies/mL)Time on RAL (months)INI DRMsPredicted drug resistance to:
HIV-1 subtype in IN
HIV-1 subtype in PR-RT
RALEVGDTGBICphylogenetic and recombination analysisStanford HIVdb genotypingphylogenetic and recombination analysisStanford HIVdb genotyping
AR_4610084.9230T97A, Y143RHLSSBBBB
AR_470449BIS5.5457G140S, Q148HHHIIBBURF_BFB
AR_4851965.0814L74M, T97A, Y143R, E138KHILLBBBB
AR_4856305.1527Y143RHSSSBBBB
AR_4880904.768G140S, Q148H, E138KHHHHBBURF_BFB
AR_4973394.7911G140S, Q148H, E138KHHHHBBBB
AR_5856_AA323RED4.7342G140S, Q148HHHIIBBURF_BFB
AR_4815944.4121T97A, Q148R, E138K, S147G, V151I/VHHHHBBFF
AR_4757362.8523L74M, N155H, V151I, G163RHHSSFBCRF29_BFCRF29_BF
AR_4775513.6930SSSSFFURF_BFCRF12_BF
AR_4819604.79SSSSFFCRF12_BFCRF12_BF
AR_4870955.317L74I/M, T97A, P142T, G163KLLSSFFURF_BFB + F
AR_4900824.4911T97A, Y143RHLSSFFCRF12_BFCRF12_BF
AR_4958524.6042L74M, T97A, Y143RHISSFFURF_BFB + F
AR_598_X785RYL4.2636G163KLLSSFFURF_BFB + F
AR_4973976.0176SSSSFFURF_BFB + F
AR_5155_T723GM6.0212L74M, T97A, Y143RHISSFFURF_BFB+F
AR_4363_W359PMME3.6810N155N/HHHSSFFCRF12_BFCRF12_BF
AR_3080_AA714DTJL3.2828T97A, G163RLLSSFFCRF17_BFB
AR_5793_AA770PG2.9522N155H, G163RHHSSFFURF_BFB + F
AR_2337_AA807FLA4.728SSSSFFURF_BFB + F
AR_3174_AA185BIL4.088SSSSFFURF_BFB
AR_49004773G140S, Q148HHHIIURF_BFFURF_BFB
AR_3013_W812BDMS3.6342V151I, N155HHHSSURF_BFBURF_BFB
AR_3302_Y937LLN4.5219G140S, Q148HHHIIURF_BFBURF_BFB
AR_568_Z708GGA4.9727G140S, Q148HHHIIURF_BFBURF_BFB
AR_6462_AA893CP4.6217L74I, G140S, Q148H, E138AHHHHURF_BFFCRF12_BFCRF12_BF
AR_6286_AA416RBBJ4.7612N155HHHSSURF_BFFURF_BFB + F
AR_3128_Z059UTA3.4231SSSSURF_BFFURF_BFB
AR_4725846.6235T97A, V151I, N155HHHSS?CRF05_DFCRF05_DFCRF05_DF
IDHIV-1 pVL (log10 copies/mL)Time on RAL (months)INI DRMsPredicted drug resistance to:
HIV-1 subtype in IN
HIV-1 subtype in PR-RT
RALEVGDTGBICphylogenetic and recombination analysisStanford HIVdb genotypingphylogenetic and recombination analysisStanford HIVdb genotyping
AR_4610084.9230T97A, Y143RHLSSBBBB
AR_470449BIS5.5457G140S, Q148HHHIIBBURF_BFB
AR_4851965.0814L74M, T97A, Y143R, E138KHILLBBBB
AR_4856305.1527Y143RHSSSBBBB
AR_4880904.768G140S, Q148H, E138KHHHHBBURF_BFB
AR_4973394.7911G140S, Q148H, E138KHHHHBBBB
AR_5856_AA323RED4.7342G140S, Q148HHHIIBBURF_BFB
AR_4815944.4121T97A, Q148R, E138K, S147G, V151I/VHHHHBBFF
AR_4757362.8523L74M, N155H, V151I, G163RHHSSFBCRF29_BFCRF29_BF
AR_4775513.6930SSSSFFURF_BFCRF12_BF
AR_4819604.79SSSSFFCRF12_BFCRF12_BF
AR_4870955.317L74I/M, T97A, P142T, G163KLLSSFFURF_BFB + F
AR_4900824.4911T97A, Y143RHLSSFFCRF12_BFCRF12_BF
AR_4958524.6042L74M, T97A, Y143RHISSFFURF_BFB + F
AR_598_X785RYL4.2636G163KLLSSFFURF_BFB + F
AR_4973976.0176SSSSFFURF_BFB + F
AR_5155_T723GM6.0212L74M, T97A, Y143RHISSFFURF_BFB+F
AR_4363_W359PMME3.6810N155N/HHHSSFFCRF12_BFCRF12_BF
AR_3080_AA714DTJL3.2828T97A, G163RLLSSFFCRF17_BFB
AR_5793_AA770PG2.9522N155H, G163RHHSSFFURF_BFB + F
AR_2337_AA807FLA4.728SSSSFFURF_BFB + F
AR_3174_AA185BIL4.088SSSSFFURF_BFB
AR_49004773G140S, Q148HHHIIURF_BFFURF_BFB
AR_3013_W812BDMS3.6342V151I, N155HHHSSURF_BFBURF_BFB
AR_3302_Y937LLN4.5219G140S, Q148HHHIIURF_BFBURF_BFB
AR_568_Z708GGA4.9727G140S, Q148HHHIIURF_BFBURF_BFB
AR_6462_AA893CP4.6217L74I, G140S, Q148H, E138AHHHHURF_BFFCRF12_BFCRF12_BF
AR_6286_AA416RBBJ4.7612N155HHHSSURF_BFFURF_BFB + F
AR_3128_Z059UTA3.4231SSSSURF_BFFURF_BFB
AR_4725846.6235T97A, V151I, N155HHHSS?CRF05_DFCRF05_DFCRF05_DF

Mutations contributing to INI susceptibility according to the Stanford HIVdb program are shown in bold. Mutations known as major are underlined.

pVL, plasma viral load; RAL, raltegravir; EVG, elvitegravir; DTG, dolutegravir; BIC, bictegravir; S, susceptible; H, high-level resistant; I, intermediate-level resistant; L, low-level resistant;—, no mutation detected by Sanger sequencing; ?, could not be confirmed by phylogenetic analysis.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close